Copper isotope of mass 64 was identified as one of the biomarkers in the blood of the patients with bladder cancer. In addition, there is a study that shows that this compound can be used in linkage with 64Cu-DOTA-rituximab to act as targeted alpha immunotherapy of CD20 positive B-cell lymphoma.
